Biohaven Ltd
BHVN
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contact
c/o Biohaven Pharmaceuticals, Inc
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
256
Stocks News & Analysis
stocks
Tesla: Shares down despite record deliveries
We think the positive third-quarter numbers will be largely offset by a weak fourth quarter.
stocks
ASX listed share dominates their industry
Shares are currently fairly valued with a Wide Moat rating.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,240.30 | 42.60 | 0.46% |
| CAC 40 | 8,056.63 | 89.68 | 1.13% |
| DAX 40 | 24,422.56 | 308.94 | 1.28% |
| Dow JONES (US) | 46,564.60 | 123.50 | 0.27% |
| FTSE 100 | 9,427.73 | 18.70 | -0.20% |
| HKSE | 27,287.12 | 431.56 | 1.61% |
| NASDAQ | 22,847.81 | 92.65 | 0.41% |
| Nikkei 225 | 44,936.73 | 385.88 | 0.87% |
| NZX 50 Index | 13,451.76 | 17.77 | 0.13% |
| S&P 500 | 6,719.43 | 8.23 | 0.12% |
| S&P/ASX 200 | 8,945.90 | 40.10 | 0.45% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |